Table 1 Patient Demographics
From: Age-related sarcoma patient experience: results from a national survey in England
|  | Bone (n = 140) | Soft Tissue (n = 418) | |||||||
|---|---|---|---|---|---|---|---|---|---|
|  | TOTAL (n = 558) | BONE (n = 140) | SOFT TISSUE (n = 418) | AYA (n = 23) | Middle-age (n = 78) | Elderly (n = 39) | AYA (n = 23) | Middle-age (n = 207 | Elderly (n = 188) |
Age | |||||||||
 Mean(SD) | 64.1 (15.5) | 57 (18.0) | 66.2 (14.0) | 26.4 (6.9) | 57.4 (8.7) | 77 (5.0) | 31.1 (5.6) | 59.7 (8.3) | 77.6 (5.5) |
Gender | |||||||||
 Male | 274 (49.1%) | 78 (55.7%) | 196 (46.9%) | 15 (65.2%) | 40 (51.3%) | 23 (59.0%) | 8 (34.8%) | 91 (44.0%) | 97 (51.6%) |
 Female | 284 (50.9%) | 62 (44.3%) | 222 (53.1%) | 8 (34.8%) | 38 (48.7%) | 16 (41.0%) | 15 (65.2%) | 116 (56.0%) | 91 (48.4%) |
Site of Disease | |||||||||
 Head/neck | 70 (12.5% | 44 (31.4%) | 26 (6.2%) | 1 (4.3%) | 24 (30.8%) | 19 (48.7%) | 2 (8.7%) | 9 (4.3%) | 15 (8.0%) |
 Thorax | 32 (5.7%) | 6 (4.3%) | 26 (6.2%) | 1 (4.3%) | 3 (3.8%) | 2 (5.1%) | 1 (4.3%) | 14 (6.8%) | 11 (5.9%) |
 Abdomen | 129 (23.1%) | n/a | 129 (30.9%) | n/a | n/a | n/a | 6 (26.1%) | 63 (30.4%) | 60 (31.9%) |
 Pelvis | 46 (8.2%) | 21 (15.0%) | 25 (6.0%) | 5 (21.7%) | 11 (14.1%) | 5 (12.8%) | 1 (4.3%) | 15 (7.2%) | 9 (4.8%) |
 Upper limb | 68 (12.2%) | 15 (10.7%) | 53 (12.7%) | 3 (13.0%) | 8 (10.3%) | 4 (10.3%) | 3 (13.0%) | 22 (10.6%) | 28 (14.9%) |
 Lower limb | 177 (31.7%) | 40 (28.6%) | 137 (32.8%) | 11 (47.8%) | 21 (26.9%) | 8 (20.5%) | 9 (39.1%) | 70 (33.8%) | 58 (30.9%) |
 Vertebral column | 6 (1.1%) | 6 (4.3%) | n/a | 1 (4.3%) | 5 (6.4%) | 0 (0.0%) | n/a | n/a | n/a |
 Skin | 9 (1.6%) | n/a | 9 (2.2%) | n/a | n/a | n/a | 1 (4.3%) | 6 (2.9%) | 2 (1.1%) |
 Unspecified | 21 (3.8%) | 8 (5.7%) | 13 (3.1%) | 1 (4.3%) | 6 (7.7%) | 1 (2.6%) | 0 (0.0%) | 8 (3.9%) |  |
Treatments Received | |||||||||
 Surgery | 502 (90.0%) | 129 (92.1%) | 374 (89.5%) | 18 (78.3%) | 75 (96.2%) | 36 (92.3%) | 19 (82.6%) | 186 (90.0%) | 169 (90%) |
 Radiotherapy | 246 (44.1%) | 58 (41.4%) | 188 (45.0%) | 13 (56.5%) | 32 (41.0%) | 13 (33.3%) | 16 (69.6%) | 95 (45.9%) | 77 (41.0%) |
 Chemotherapy | 201 (36.0%) | 55 (39.3%) | 146 (34.9%) | 20 (87.0%) | 33 (42.3%) | 2 (5.1%) | 17 (73.9%) | 81 (39.1%) | 48 (25.5%) |
 Other | 27 (4.8%) | 10 (7.1%) | 17 (4.1%) | 2 (8.7%) | 5 (6.4%) | 3 (7.7%) | 0 (0.0%) | 11 (5.3%) | 6 (3.2%) |
Follow-up | |||||||||
  < 3 monthly | 89 (17.4%) | 37 (28.2%) | 52 (13.7%) | 7 (30.4%) | 17 (23.9%) | 13 (35.1%) | 3 (13.4%) | 30 (15.8%) | 19 (11.2%) |
 3 monthly | 232 (45.4%) | 49 (37.4%) | 183 (48.2%) | 9 (39.1%) | 32 (45.1%) | 8 (21.6%) | 12 (57.1%) | 94 (49.5%) | 77 (45.6%) |
  > 3–6 monthly | 128 (25.0%) | 34 (26.0%) | 94 (24.7%) | 5 (21.7%) | 18 (25.4%) | 11 (29.7%) | 3 (14.3%) | 41 (21.6%) | 50 (29.6%) |
 Annual | 23 (4.5%) | 6 (4.6%) | 17 (4.5%) | 2 (8.7%) | 1 (1.4%) | 3 (0.0%) | 0 (0.0%) | 11 (5.8%) | 6 (3.6%) |
 Never | 12 (2.3%) | 1 (0.8%) | 11 (2.9%) | 0 (0%) | 1 (1.4%) | 0 (0%) | 1 (4.8%) | 3 (1.6%) | 7 (4.1%) |
 Variable | 27 (5.3%) | 4 (3.1%) | 23 (6.1%) | 0 (0%) | 2 (2.8%) | 2 (5.4%) | 2 (9.5%) | 11 (5.8%) | 10 (5.9%) |